Clinical Trials on Bladder Oversensitivity

Total 3102 results

Jiangsu Yahong Meditech Co., Ltd aka Asieris

Active, not recruiting

Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients (ACCRUE)

Non-muscle Invasive Bladder Cancer

China
Jeil Pharmaceutical Co., Ltd.

Completed

The Safety and PK Characteristics of the Co-administration of JLP-2002 and Comparator in Healthy Volunteers

Overactive Bladder(OAB)

Korea, Republic of
Jiangsu Yahong Meditech Co., Ltd aka Asieris

Completed

Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy

Non-muscle Invasive Bladder Cancer
En Chu Kong Hospital

Completed

Herbal Patch for Overactive Bladder

Overactive Bladder Syndrome

Taiwan
University of California, San Diego

Completed

Trial of Maintenance Therapy With Posterior Tibial Nerve Stimulation for Overactive Bladder

Overactive Bladder Syndrome

United States
Peking University

Withdrawn

PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer

Invasive Bladder Cancer Stage IV

China
Tongji Hospital

Unknown

"En Bloc" Resection of NMIBC: a Prospective， Single Centre，Randomized Study

Non-muscle Invasive Bladder Cancer
Beijing Pins Medical Co., Ltd
Beijing Hospital

Unknown

Clinical Trial of Sacral Neuromodulation for Treatment of Refractory Overactive Bladder (OAB)

Refractory Overactive Bladder

China
Astellas Pharma Inc

Terminated

A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)

Bladder Function

United States
University of Zurich

Completed

Intravesical Injection of Botox for Treating Therapy Refractory Overactive Bladder in Females

Overactive Bladder Syndrome

Switzerland
Novartis

Completed

A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder

Overactive Bladder Syndrome

United States
Novartis
Procter and Gamble

Completed

Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder

Overactive Bladder (OAB)

United States
Zhujiang Hospital

Recruiting

RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients

Bladder Cancer | Muscle-Invasive Bladder Carcinoma

China
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Bladder Cancer | Bladder Tumor | Muscle-Invasive Bladder Cancer

Russian Federation, China, Germany, Italy, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Greece, Israel, Mexico, Netherlands, Poland, Spain, United Kingdom
Tianjin Medical University Second Hospital

Recruiting

Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Cancer: A Multicenter Study

Muscle Invasive Bladder Cancer Urothelial Carcinoma

China
Assiut University

Unknown

Skipping BCG for T1a Urinary Bladder Tumor.

Superficial Bladder Cancer t1a
University Hospital, Clermont-Ferrand

Unknown

Evaluation of Professional Practices in the Treatment of Refractory Idiopathic Overactive Bladder at the Dose of 50 Units (TOX50IUU) (TOX50IUU)

Bladder, Overactive

France
Institut Claudius Regaud
Cepheid

Unknown

Effect on Xpert® Bladder Test of Urines Inflammatory Milieu Induced by BCG Treatment of Patients With NMIBC (CEPHEID)

Non Muscle Invasive Bladder Cancer | Treatment by BCG

France
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

Blue Laser -5ala Photodynamic Therapy (PDT) in High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BL-PDT-RCT)

Non-muscle-invasive Bladder Cancer

China
Jørgen Bjerggaard Jensen
University of Aarhus

Recruiting

Outpatient Laser Ablation of Recurrent Non-muscle Invasive Bladder Cancer (OPTIMA)

Non-Muscle Invasive Bladder Cancer

Denmark
Taipei Veterans General Hospital, Taiwan

Recruiting

Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial

Overactive Bladder Syndrome

Taiwan
Shenzhen Geno-Immune Medical Institute

Unknown

Intervention of Bladder Cancer by CAR-T

Bladder Cancer | Urothelial Carcinoma Bladder

China
Paolo Puppo

Completed

Prospective Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging

Non Muscle Invasive Bladder Cancer

Italy
Buddhist Tzu Chi General Hospital

Unknown

Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

Overactive Bladder Syndrome

Taiwan
Radboud University Medical Center

Withdrawn

Overactive Bladder (OAB) Drink Advice Study

Overactive Bladder Syndrome

Netherlands
Pfizer

Completed

Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome

Overactive Bladder Syndrome

Germany
Pfizer

Completed

A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome

Overactive Bladder Syndrome

Germany
Jonsson Comprehensive Cancer Center
AstraZeneca

Active, not recruiting

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Stage IV Bladder Cancer AJCC v8 | Stage IVA Bladder Cancer AJCC v8 | Stage IVB Bladder Cancer AJCC v8 | Bladder Urothelial Carcinoma

United States
Emory University

Terminated

Adjuvant Radiation for High Risk Bladder Cancer

Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Squamous Cell Carcinoma of the Bladder

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca

Completed

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Adenocarcinoma of the Bladder | Squamous Cell Carcinoma of the Bladder | Metastatic Bladder Cancer | Non-Transitional Cell Carcinoma of the Urothelial Tract | Small Cell of the Bladder

United States
University of Southern California
National Cancer Institute (NCI); GlaxoSmithKline

Terminated

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

Recurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder

United States
University of California, Los Angeles

Recruiting

Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study

Bladder Cancer | Kidney Failure | Bladder, Neurogenic | Bladder Disease

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...
Radboud University Medical Center

Recruiting

Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer (TROJAN)

Bladder Cancer | Superficial Bladder Cancer

Netherlands
Fundacion Oncosur
Apices Soluciones S.L.

Active, not recruiting

Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE) (BladderGATE)

Invasive Bladder Cancer

Spain
Gérard Amarenco

Completed

Effect of Bladder Filling on Rectal Contractions During Cystometry

Bladder Dysfunction

France
Kangbuk Samsung Hospital

Withdrawn

Combined Dexmedetomidine and Glycopyrrolate Therapy

Bladder Irritable
Assiut University

Completed

Transurethral Versus Percutaneous Endoscopic Management of Bladder Stones in Boys

Pediatric Bladder Stones

Egypt
Anchiano Therapeutics Israel Ltd.

Terminated

Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC

Non-muscle Invasive Bladder Cancer (NMIBC)

United States
Pfizer

Completed

A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects

Treatment of Overactive Bladder

United States
Medical University of Warsaw

Unknown

A Retrospective Analysis of Spinal Anaesthesia for TURBT Procedures in Elderly Patients

Bladder Tumor | Transurethral Resection | Spinal Anaesthesia

Poland
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Astellas Pharma Inc; Seagen...

Recruiting

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Stage III Bladder Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Metastatic Bladder Carcinoma | Urachal Adenocarcinoma | Locally Advanced Bladder Carcinoma | Malignant Renal Pelvis Neoplasm | Malignant Ureter Neoplasm | Malignant Urethral Neoplasm and other conditions

United States
Burzynski Research Institute

Terminated

Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder

Stage IV Bladder Cancer

United States
Astellas Pharma Europe Ltd.

Completed

Vesitirim™ in Men Postmarketing Observational Study (VIM)

Overactive Bladder (OAB) | Lower Urinary Tract Symptoms (LUTS)

Ireland
Hospital Italiano de Buenos Aires

Recruiting

Virtual Bladder Training for Overactive Bladder Syndrome in Women. Which Symptom Responds Better?

Overactive Bladder Syndrome

Argentina
Centre Hospitalier de Roubaix

Not yet recruiting

Effectiveness of HYPNOsis Masks During Botulinum TOXin Injections in Idiopathic Overactive Bladder(HypnoTox) (HypnoTox)

Idiopathic Overactive Bladder
Pacific Edge Limited

Recruiting

CxBladder Surveillance of Intermediate and High-Risk Bladder Cancer Patients

Urothelial Bladder Cancer

United States
Far Eastern Memorial Hospital

Recruiting

Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome

Overactive Bladder Syndrome

Taiwan
Mansoura University

Recruiting

Omega-3 Polyunsaturated Fatty Acids and Non-Muscle Invasive Bladder Cancer

Non-Muscle Invasive Bladder Cancer

Egypt
Mansoura University

Recruiting

Low Energy Shock Wave Therapy and Non-Muscle Invasive Bladder Cancer

Non-Muscle Invasive Bladder Cancer

Egypt
Institut Paoli-Calmettes

Not yet recruiting

Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer (PREVERT)

Non-muscle-invasive Bladder Cancer

Clinical Trials on Bladder Oversensitivity

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations